Was ist die Webseite?

Convatec Wound

Startseite
Deutschland
Bremen
Convatec Wound

Kontaktinformationen, Karte und Wegbeschreibungen, Kontaktformulare, Öffnungszeiten, Dienstleistungen, Bewertungen, Fotos, Videos und Ankündigungen von Convatec Wound, Medizin und Gesundheit, Bremen.

At Convatec, is our promise to patients & healthcare providers, as we deliver pioneering trusted medical solutions to improve the lives we touch. .

08/06/2026

Infections, present in 60% of diabetic foot ulcers (DFUs), further complicate the already poor outcomes of DFUs— particularly as persons with diabetes may have an already impaired immune system.¹ ²

In Episode 2 of our DFU Spotlight Series, the experts break down how spreading infection, a constantly evolving challenge in DFUs, complicates healing outcomes even further.¹ ³

🎥 Hear from the experts on what makes infection such a complicated outcome.

1. Edmonds M et al. The current burden of diabetic foot disease. J Clin Orthop Trauma. 2021;17:88-93.

2. Monaghan MG et al. Thou shall not heal: Overcoming the non-healing behaviour of diabetic foot ulcers by engineering the inflammatory microenvironment. Adv Drug Deliv Rev. 2023;203:115120.

3. Baig MS et al. An Overview of Diabetic Foot Ulcers and Associated Problems with Special Emphasis on Treatments with Antimicrobials. Life (Basel). 2022;12(7):1054.

AP-79201-GBL-ENG-v1

08/06/2026

We're proud to be a partner of Legs Matter during Legs Matter Week 2026.

An estimated 3.8 million people in the UK are living with a wound that requires NHS management.¹

This week, we're supporting one powerful message:

"It doesn't have to be this way"

👉 Read our latest blog to learn more: https://brnw.ch/21x3ask

05/06/2026

Part of being forever caring is being forever innovative.

At the joint EWMA-DEWU congress this year we had the immense honour of having ConvaNiox™, our novel, multimodal, nitric oxide-generating wound dressing1, be awarded the “Most Innovative Product” award at the 2026 Innovation Catwalk (Laufsteg der Innovationen) 🏆

This recognition highlights our commitment to continue advancing and shaping the future of wound care. We are proud of the teams behind this achievement and grateful to the community for this recognition.

European Wound Management Association - EWMA

References:
1. Convatec receives regulatory approval for ConvaNiox™. https://brnw.ch/21x377Y. Published 2025. https://brnw.ch/21x377Z

AP-80274-GBL-ENG-v1

28/05/2026

Same knees, same hospital, two very different results.

Terry had a successful knee replacement in 2024 with Aquacel Surgical supporting his recovery. In 2025, he had the same procedure on his right knee. Unfortunately, a different dressing was used which caused Terry issues. Due to this change in dressing Terry reported that he lacked trust in the dressing for simple things like walking upstairs or bending his leg.

When post-operative outcomes differ, it’s worth looking at what’s changed.

27/05/2026

85% of diabetes-related amputations occur as a result of diabetic foot ulcers (DFUs)¹. Yet DFUs often remain misunderstood outside clinical settings.

In our first episode of the DFU Spotlight Series, global experts unpack why DFUs are so widespread — affecting an estimated 40–60 million people² — and what makes them particularly challenging due to associated comorbidities.

🎥 Watch the experts explain the scale of DFUs and why early identification matters.

Stay tuned for Episode 2, where we explore the common outcome of infection.

1. Voza FA et al. Fibroblasts in diabetic foot ulcers. Int J Mol Sci. 2024;25(4):2172.

2. Jupiter DC et al. The impact of foot ulceration and amputation on mortality in diabetic patients. I: From ulceration to death, a systematic review. Int Wound J. 2016;13(5):892–903.

AP-79201-GBL-ENG-v1

20/05/2026

Hear from Terry, who, aged 60 had a total left knee replacement in 2024 following an arthritis diagnosis.

Aquacel™ Surgical was applied to the incision, which made him feel comfortable with the dressing and allowed him to fully complete his physio without any stretching, so much so he described it as a “second skin”.

18/05/2026

Debridement may help reduce infection risk and accelerate healing

In a Randomised Controlled Trial on hard‑to‑heal Venous Leg Ulcers, Aquacel® Ag+ Extra™ with Antibiofilm MORE THAN SILVER™ Technology demonstrated superior slough reduction and complete debridement compared with Cutimed® Sorbact®.

Antibiofilm performance united with debridement. See the results.

13/05/2026

💜 Performance You Can Rely On.

At , during our symposium “A Year of Healing”, we discussed what makes ConvaFoam™ unique.¹

The only foam combining three technologies in one dressing:
✔️Hydrofiber
✔️Superabsorber
✔️ConvaTac™

Early NHS data demonstrated that ConvaFoam™ achieved 98% of clinical objectives, significantly reduced dressing changes and decreased overall resource use and spend. ²

During the session, Shauna Roberts, BSc (Hons), Advanced Wound Care Technical Lead, shared the research and development behind ConvaFoam™ innovation. ¹

Read more here: https://brnw.ch/21x2soh

European Wound Management Association - EWMA

References:
¹ Convatec. A Year of Healing: Advancing wound care with a next-generation foam dressing. EWMA 2026 ConvaFoam™ Symposium Programme Information.

² Hughes M, Wilkins J, Fisher J, Rodger R. Early outcomes of implementing a new multilayer foam dressing in an acute setting: assessing clinical and financial impact through value-based procurement. EWMA 2026 Abstract [1196].

AP-79504-GBL-ENG-v1

11/05/2026

Join us at the 21st Malvern Diabetic Foot Conference where we will be hosting a symposium on ConvaNiox™, our multimodal, nitric oxide-generating dressing for diabetic foot ulcers (DFUs).¹

Chaired by Dr Chris A. Manu and joined by Daniel Metcalf our session will begin with an explanation of the multimodal features of ConvaNiox™ that have contributed to the superior healing outcomes compared to standard of care in an RCT.²

A post-hoc analysis will present further data on ulcer duration, concomitant antibiotic usage and infection status, highlighting potential use strategies for ConvaNiox™.

Lastly, we’ll hear about experiences using ConvaNiox™ that show its strength in tackling a range of challenging DFUs.

📍Join us at Malvern on the 14th of May for the full session

🔗 Learn more about ConvaNiox™ here: https://brnw.ch/21x2nSN

References:
1. ConvaNiox Claims Summary, RPT-088112 v2.0. Data on file. Convatec Inc., 2025.

2. Edmonds ME, et al. Multicenter, randomized controlled, observer-blinded study of a nitric oxide generating treatment in foot ulcers of patients with diabetes—ProNOx1 study. Wound Repair Regen. 2018;26:228–237.

AP-79967-GBL-ENG-v1

11/05/2026

What a week at 💜

From inspiring conversations and shared learning to innovation on the stand and moments that reminded us why this community matters, EWMA 2026 was truly energising.

It was a privilege to connect with clinicians, partners, speakers, and innovators from across the wound care community - all united by a shared commitment to improving outcomes for patients worldwide. From insightful discussions at our booth to meaningful exchanges throughout the congress, our team left feeling motivated by the passion, collaboration, and expertise on display.

Thank you to everyone who engaged with us throughout the week and continues to move wound care forward every day. We’re proud to be part of this community and the collective commitment to advancing care together.

Here’s a look back at some of our highlights from EWMA 2026.

European Wound Management Association - EWMA

Adresse

Bremen
28307

Webseite

https://www.convatec.com/en-gb/wound-skin/

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von Convatec Wound erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.